期刊文献+

二甲双胍联合西格列汀或吡格列酮对肥胖型2型糖尿病的疗效比较 被引量:5

Comparing effects on type 2 diabetes of metformin either with sitagliptin or pioglitazone
下载PDF
导出
摘要 目的:比较西格列汀与吡格列酮分别联用二甲双胍治疗二甲双胍单药控制不佳的肥胖型2型糖尿病的疗效。方法:60例2型糖尿病肥胖患者在服用二甲双胍片的前提下,随机分为西格列汀组(n=30)和吡格列酮组(n=30),分别给予西格列汀片与吡格列酮片口服,检测入组时和治疗12周后两组糖化血红蛋白、空腹及餐后血糖水平、低血糖例数、体重指数等数据。结果:治疗12周后,西格列汀组患者的糖化血红蛋白、空腹及餐后血糖、体重指数均比吡格列酮组改善明显,两组均无低血糖发生。结论:西格列汀联用二甲双胍片治疗肥胖型2型糖尿病的疗效优于吡格列酮片联用二甲双胍片。 Objective :To comparing efficacy differences combined with metformin between sitagliptin and pioglitazone on obese type 2 diabetes mellitus that had a poorly control with metformin monotherapy. Methods:60 cases of obese patients with type 2 diabetes mellitus in the premise of using metformin were randomly divided into sitagliptin group(n=30)and pioglitazone group(n=30). Medical data such as Glycosylated hemoglobin,fasting and postprandial blood glucose level, the number of cases of hypoglycemia, BMI were recorded before grouping and after a treatment of 12 weeks,. Results:Glycosylated hemoglobin, fasting and postprandial blood glucose levels, BMI levels in patients of sitagliptin group were significantly improved in 12 weeks compared with pioglitazone group. Hypoglycemia did not happen in both group. Conclusion: Combined with metformin, the efficacy of Sitagliptin is better than that of pioglitazone on obese type 2 diabetes mellitus.
出处 《北方药学》 2015年第5期134-135,共2页 Journal of North Pharmacy
基金 广东省佛山市科技局2013年佛山市医学类科技攻关项目 项目编号201308245
关键词 西格列汀 吡格列酮 二甲双胍 肥胖型2型糖尿病 sitagliptin Pioglitazone Metformin Obese type 2 diabetes mellitus
  • 相关文献

参考文献13

  • 1Xu Y,Wang L,He J,et al. Prevalence and Control of Diabetes in Chinese Adults[J]. JAMA, 2013,310(9):948-958.
  • 2International Diabetes Federation. Diabetes Atlas 6th Edition 2013 Update.
  • 3American Association of Clinical Endocrinologists.Comprehen- sive Diabetes Management Algorithm 2013 [J].published in Endocr Pract,2013,19(Suppl 1 ) : 1-48.
  • 4International Diabetes Federation. Global Guideline for Type 2 Diabetes 2012.
  • 5中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,22(8). 被引量:6688
  • 6Dormandy J, Bhattacharya M, van Troostenbuvg de Bmyn AR, et al.Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes:an overview of data from PROactive [J].Drug saf, 2009,32(3) : 187-202.
  • 7邹大进.二肽基肽酶Ⅳ抑制剂西格列汀上市七年循证证据回顾[J].中华糖尿病杂志,2014,6(1):61-64. 被引量:8
  • 8孙娟,李伟.西格列汀治疗对2型糖尿病患者胰岛素抵抗的影响[J].中国老年学杂志,2013,33(8):1886-1887. 被引量:10
  • 9Charbonnel B, Karasik A,Liu J, et al.Efficacy and safety of the dipeptide peptidase-4 inhibitor sitagliptin added to ongoing met- formin therapy in patients with type 2 diabetes inadequately con- trolled with metformin alone [J].Diabetes Care,2006,29 (12): 2638-2643.
  • 10杜瑞琴,李宏亮,杨文英,萧建中,王冰,楼大钧,白秀平,潘琳.吡格列酮对胰岛α细胞胰岛素抵抗的影响[J].中华内分泌代谢杂志,2008,24(1):29-33. 被引量:19

二级参考文献113

共引文献6748

同被引文献45

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部